Incanthera plc

Pre-Annual General Meeting Information • Nov 6, 2025

National Storage Mechanism | Additional information

RNS Number : 3941G

Incanthera PLC

06 November 2025

6 November 2025

Incanthera plc

("Incanthera" or the "Company")

AGM 2025 Update

Incanthera plc (AQSE: INC), the Company focused on innovative technologies in dermatology and oncology, announces that at its Annual General Meeting, being held at 11am on 7 November 2025 at the offices of Gateley Plc, 1 Paternoster Square, London, EC4M 7DX, the Company will give a short presentation on its current commercial status and opportunities.

The AGM presentation will be made to shareholders who attend in person and who have registered for virtual attendance via the Investor Meet platform.

Following the presentation a short Q&A session will be conducted.

The presentation will be made available on the Company's website, www.incanthera.com  and a recording of the full AGM will be posted following the formal meeting.

For further information please contact:

Incanthera plc www.incanthera.com Tim McCarthy, Chairman [email protected] Simon Ward, Chief Executive Officer [email protected] Suzanne Brocks, Head of Communications [email protected]	+44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:  Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes	+44 (0) 20 7213 0880
Broker:  Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	+44 (0) 20 3650 3650/51

Notes to Editors

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.

Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.

The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

About Skin + CELL 

Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

www.skinandcell.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEAEFSEDKSFAA